My First 24 Hours on Tirzepatide
US$ 21.38
tirzepatide news september 27 2025 New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss ADA 2025: Advances in Type
Description
Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review
The drug also shows promising cost-effectiveness when compared to established therapies, such as semaglutide, and pharmacokinetic stability in populations with mild or moderate hepatic impairment
For the study, researchers analyzed data on more than 638,000 patients with a history of pancreatitis
Marso, S
